Background Limits on the frequency of whole blood donation exist primarily to safeguard
donor health. However, there is substantial variation across blood services in the maximum …

Introduction The lack of approved specific therapeutic agents to treat coronavirus disease (COVID‐19)
associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) …

Plasma‐derived medicinal products (PDMPs) are life‐saving and life‐improving therapies,
but the raw material is in short supply: Europe depends on importation from countries …

Each year, blood transfusions save millions of lives. However, under current blood-matching
practices, sensitization to non–self-antigens is an unavoidable adverse side effect of …

The use of peripheral blood stem cells instead of bone marrow as the source of haemopoietic
cells for allogeneic transplantation is being increasingly explored. We have analysed data …

Background The INTERVAL trial showed that, over a 2-year period, inter-donation intervals
for whole blood donation can be safely reduced to meet blood shortages. We extended the …

Background We have recently completed an evaluation of the safety and feasibility of intravenous
delivery of autologous bone marrow in patients with progressive multiple sclerosis (MS…

Background The interpretation of trial results can be helped by understanding how generalisable
they are to the target population for which inferences are intended. INTERVAL, a large …

The Transfusion 2024 plan outlines key priorities for clinical and laboratory transfusion practice
for safe patient care across the NHS for the next 5 years. It is based on the outcomes of a …

Following recognition that blood, blood components, tissues and organs donated by
infected donors could transmit infectious prions causing variant Creutzfeldt‐Jakob Disease (vCJD), …